-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 9, Renfu Medicine issued an announcement stating that its holding subsidiary, Yichang Renfu, had received the US FDA’s approval number for venlafaxine hydrochloride sustained-release capsules, which are suitable for various types of depression, including those accompanied by anxiety.
Depression and generalized anxiety disorder
.
Yichang Renfu submitted an ANDA application for venlafaxine hydrochloride sustained-release capsules in 2020, with a cumulative R&D investment of approximately US$2 million
.
According to statistics from IQVIA, the total sales of venlafaxine hydrochloride sustained-release capsules in the U.